ArticleInternational journal for parasitology. Drugs and drug resistance2018
Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
Article in International journal for parasitology. Drugs and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Licochalcone A as a Potential Anti-Biomolecules · 2026Article
- Prenylated chalcone analog-mediated Inhibition of Toxoplasma gondii growth in human trophoblast cell line and villous explants.Scientific reports · 2025Article
- Effect of the flavonoid compound glabridin on tachyzoites and bradyzoites of Toxoplasma gondii.Parasites & vectors · 2025Article
- Identification of a New Pentafluorosulfanyl-Substituted Chalcone with Activity Against Hepatoma and Human Parasites.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.Pharmaceutics · 2024Review
- Anti-Toxoplasma gondii effects of XYP1-derived peptides and regulatory mechanisms of XYP1.Parasites & vectors · 2024Article
- Effect of the mitochondrial uncoupling agent BAM15 against the Toxoplasma gondii RH strain and Prugniaud strain.Parasites & vectors · 2024Article
- Licochalcone A: a review of its pharmacology activities and molecular mechanisms.Frontiers in pharmacology · 2024Review
- Synthesis andFrontiers in chemistry · 2024Article
- Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.BioMed research international · 2022Article
- Article
- Article
- Myrislignan Induces Redox Imbalance and Activates Autophagy inFrontiers in cellular and infection microbiology · 2021Article
- Licarin-B Exhibits Activity Against theFrontiers in cell and developmental biology · 2021Article
- Shenjinhuoxue Mixture Attenuates Inflammation, Pain, and Cartilage Degeneration by Inhibiting TLR-4 and NF-Oxidative medicine and cellular longevity · 2021Article
- Urolithin-A attenuates neurotoxoplasmosis and alters innate response towards predator odor.Brain, behavior, & immunity - health · 2020Article
- ROS-mediated NLRP3 inflammasome activation participates in the response against Neospora caninum infection.Parasites & vectors · 2020Article
- Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.Journal of natural products · 2020Article
- Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen ofBiomedicines · 2020Article
- Licochalcone a Exhibits Leishmanicidal ActivityFrontiers in veterinary science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii, an obligate intracellular protozoan, is the causative agent of toxoplasmosis, which can cause serious public health problems. The current drugs used to treat toxoplasmosis have many limitations. This study evaluated the anti-T. gondii activity and potential mechanism of Licochalcone A (Lico A) in vitro and in vivo. The safe concentration of Lico A in HFF cells was determined by MTT cell viability assays. The presence of T. gondii was assessed by qPCR and Giemsa staining. Azithromycin and sulfadiazine, commonly used effective treatments, served as drug controls. T. gondii ultrastructural alterations were observed by electron microscopy. The anti-T. gondii activity of Lico A was evaluated using an in vivo mouse infection model. In vitro, Lico A had no negative effect on host cell viability at concentrations below 9 μg/mL; however, it did inhibit T. gondii proliferation in a dose-dependent manner, with a 50% inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.